ResMed (RMD) to Release Earnings on Thursday

Key Points

• ResMed is set to release its Q1 2026 earnings on Thursday, October 30th, with an expected earnings of $2.49 per share and revenue of $1.3332 billion.
• The company has recently increased its quarterly dividend from $0.53 to $0.60 per share, with a yield of 0.9% and a payout ratio of 25.24%.
• ResMed's stock has seen a slight decline of 0.7% and currently has a market cap of $38.87 billion, with a consensus target price of $294.55 among analysts.

ResMed (NYSE:RMD - Get Free Report) is expected to post its Q1 2026 results after the market closes on Thursday, October 30th. Analysts expect ResMed to post earnings of $2.49 per share and revenue of $1.3332 billion for the quarter. Investors may review the information on the company's upcoming Q1 2026 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical equipment provider reported $2.55 earnings per share for the quarter, topping analysts' consensus estimates of $2.47 by $0.08. ResMed had a net margin of 27.22% and a return on equity of 25.62%. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.33 billion. During the same period in the prior year, the company earned $2.08 EPS. The firm's revenue was up 10.2% on a year-over-year basis. On average, analysts expect ResMed to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

ResMed Stock Down 0.7%

Shares of ResMed stock opened at $266.32 on Thursday. The company has a fifty day moving average price of $276.14 and a 200 day moving average price of $258.27. The company has a current ratio of 3.44, a quick ratio of 2.53 and a debt-to-equity ratio of 0.11. ResMed has a twelve month low of $199.92 and a twelve month high of $293.81. The stock has a market cap of $38.87 billion, a price-to-earnings ratio of 28.00, a price-to-earnings-growth ratio of 1.79 and a beta of 0.83.

ResMed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 18th. Investors of record on Thursday, August 14th were given a dividend of $0.60 per share. This is a positive change from ResMed's previous quarterly dividend of $0.53. The ex-dividend date of this dividend was Thursday, August 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. ResMed's dividend payout ratio is currently 25.24%.

Insider Activity

In related news, General Counsel Michael J. Rider sold 100 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $274.36, for a total transaction of $27,436.00. Following the sale, the general counsel owned 11,327 shares in the company, valued at $3,107,675.72. This represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Hernandez sold 2,575 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $287.10, for a total transaction of $739,282.50. Following the sale, the director owned 4,045 shares in the company, valued at approximately $1,161,319.50. This trade represents a 38.90% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,743 shares of company stock worth $5,284,514. 0.65% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ResMed

Several large investors have recently made changes to their positions in the company. Captrust Financial Advisors increased its stake in shares of ResMed by 6.2% in the second quarter. Captrust Financial Advisors now owns 510,058 shares of the medical equipment provider's stock valued at $131,595,000 after purchasing an additional 29,729 shares during the period. BNP Paribas Financial Markets increased its stake in shares of ResMed by 13.0% in the second quarter. BNP Paribas Financial Markets now owns 350,417 shares of the medical equipment provider's stock valued at $90,408,000 after purchasing an additional 40,399 shares during the period. Alliancebernstein L.P. increased its stake in shares of ResMed by 24.2% in the second quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider's stock valued at $73,808,000 after purchasing an additional 55,790 shares during the period. California State Teachers Retirement System boosted its holdings in shares of ResMed by 0.4% in the second quarter. California State Teachers Retirement System now owns 232,518 shares of the medical equipment provider's stock valued at $59,990,000 after acquiring an additional 952 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its stake in shares of ResMed by 2.8% during the second quarter. CANADA LIFE ASSURANCE Co now owns 166,625 shares of the medical equipment provider's stock valued at $43,008,000 after acquiring an additional 4,595 shares during the period. Institutional investors and hedge funds own 54.98% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on RMD shares. William Blair raised shares of ResMed to a "strong-buy" rating in a research report on Friday, August 1st. KeyCorp boosted their price objective on shares of ResMed from $274.00 to $298.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Weiss Ratings reiterated a "buy (b-)" rating on shares of ResMed in a report on Wednesday, October 8th. Stifel Nicolaus boosted their price objective on shares of ResMed from $240.00 to $270.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Finally, Royal Bank Of Canada boosted their price objective on shares of ResMed from $294.00 to $300.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, ResMed currently has a consensus rating of "Moderate Buy" and a consensus target price of $294.55.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.